Fate Therapeutics (FATE) Total Non-Current Liabilities (2012 - 2026)

Fate Therapeutics' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $284.6 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 28.58% year-over-year to $284.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $284.6 million (down 28.58% YoY) and the FY2025 annual result came in at $318.7 million, down 27.61% from the prior year.
• Total Non-Current Liabilities was $284.6 million for Q1 2026 at Fate Therapeutics, down from $318.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $842.6 million in Q1 2022 and bottomed at $284.6 million in Q1 2026.
• A 5-year average of $534.5 million and a median of $527.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities declined 9.08% — and 2025, when it tumbled 30.48%.
• Fate Therapeutics' Total Non-Current Liabilities stood at $701.7 million in 2022, then slipped by 28.05% to $504.9 million in 2023, then dropped by 12.82% to $440.2 million in 2024, then decreased by 27.61% to $318.7 million in 2025, then slipped by 10.7% to $284.6 million in 2026.
• Business Quant data shows FATE's Total Non-Current Liabilities at $284.6 million in Q1 2026, $318.7 million in Q4 2025, and $343.3 million in Q3 2025.